Bromantane vs Modafinil
Moderate Research vs FDA Approved
monitor Researched · 90% Both compounds enhance dopaminergic signaling, though through distinct mechanisms (modafinil via DAT inhibition, bromantane via TH upregulation). Combining them may result in excessive dopaminergic stimulation, potentially causing anxiety, overstimulation, or insomnia. If combining, start with lower doses of each and monitor closely.
Molecular Data
Bromantane Modafinil
Weight 277.18 Da 273.35 Da
Half-life ~11 hours ~12-15 hours
Type Adamantane-bromophenyl derivative (C16H20BrN) Diphenylmethylsulfinylacetamide (C15H15NO2S)
Key Benefits
Bromantane
01 Upregulates endogenous dopamine synthesis via tyrosine hydroxylase gene expression, producing sustained motivational drive without depletion
02 Anxiolytic properties reduce stress and anxiety without sedation, creating a state of calm, focused energy
03 Actoprotective effects improve both physical and mental performance under stressful or fatiguing conditions
04 Very low abuse and dependence potential due to the absence of acute monoamine release or reuptake inhibition
05 Minimal tolerance development compared to traditional stimulants, supporting longer-term use patterns
06 Smooth onset and offset with no crash or rebound effects
Modafinil
01 Sustained wakefulness and alertness for 10-15 hours without the jitteriness of traditional stimulants
02 Enhanced executive function, working memory, and decision-making under fatigue
03 Improved focus and concentration during prolonged cognitive tasks
04 Reduced impulsivity and improved task completion in sleep-deprived individuals
05 Low abuse potential relative to amphetamine-class stimulants (Schedule IV)
06 Minimal impact on normal sleep architecture when taken in the morning
Side Effects
Bromantane
Insomnia or difficulty falling asleep (if taken too late in the day)
Mild anxiety or restlessness at higher doses (above 100 mg)
Mild headache (uncommon, typically transient)
Modafinil
Headache (most frequently reported side effect, often dose-dependent)
Insomnia (particularly if taken too late in the day)
Anxiety and nervousness
Appetite suppression and mild nausea
Dry mouth
Dizziness
Gastrointestinal discomfort (diarrhea, abdominal pain)
Contraindications
Known hypersensitivity to bromantane or adamantane derivatives
Pregnancy and breastfeeding (insufficient safety data)
Severe hepatic impairment
Concurrent use of MAO inhibitors (theoretical risk of excessive dopaminergic activity)
Known hypersensitivity to modafinil or armodafinil
History of Stevens-Johnson Syndrome, TEN, or DRESS with prior modafinil/armodafinil use
Severe hepatic impairment (dose reduction required in moderate impairment)
Unstable angina or recent myocardial infarction
Left ventricular hypertrophy or clinically significant mitral valve prolapse with prior stimulant use
Pregnancy (limited human data; animal studies show teratogenicity at high doses)
Research Evidence
Bromantane Modafinil
Status Moderate Research FDA Approved
References 5 studies 5 studies
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.